Organization Profile

Related Organization(s)

You just read:

Eisai Announces Canadian Launch of Halaven™ (eribulin mesylate) Injection For The Treatment of Metastatic Breast Cancer

News provided by

Eisai Limited

Apr 24, 2012, 07:00 ET